A new published study suggests that peritoneal mesothelioma patients treated at academic medical centers survive much longer than those who get their care at community hospitals. The study was conducted by Harvard Medical School researchers at Brigham and Women’s Hospital in Boston. Peritoneal mesothelioma is a rare and aggressive cancer of abdominal membranes. There is no known cure. The new study compared outcomes and survival among more than 2,600 mesothelioma patients. Patients were treated at high-volume academic hospitals or community cancer centers. The results suggest that academic medical centers consistently provide more advanced and potentially life-extending care for this complex cancer. Experience is Critical for Mesothelioma Care Malignant mesothelioma is the name for cancers that occur on internal membranes. It … Continue reading Academic Medical Centers Extend Peritoneal Mesothelioma Survival
A recent study found no link between mesothelioma survival and exposure to pleural fluid. But that does not necessarily mean the link doesn’t exist. Pleural fluid is also called pleural effusions or “water on the lungs”. It is extra fluid that builds up around the lungs. It is common in people with heart failure, kidney or liver disease, pleural mesothelioma and some other kinds of cancer. Pleural effusions are usually treated as an uncomfortable mesothelioma symptom. Draining the fluid can help patients breathe easier. But researchers at Oxford University wondered whether the pleural fluid itself could shorten mesothelioma survival. In this study, the answer appears to be no. But the researchers warn this may not be the final word on … Continue reading Does Pleural Fluid Exposure Affect Mesothelioma Survival?
The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102. Norweigian drug maker Targovax recently released the final survival data from a two-year study of ONCOS-102 in people with malignant pleural mesothelioma. Eighteen months into the study, it looked like some of the patients on the immunotherapy treatment would live longer than two years. Now that the ONCOS-102 study has passed the two year mark, researchers say median survival may be even longer. Average survival is a year or less on standard mesothelioma therapies. This makes the news about ONCOS-102 especially exciting. Standard of Care Versus Immunotherapy Treatment Malignant mesothelioma is an aggressive malignancy with a poor prognosis. Even patients in overall good health face a grim outlook. … Continue reading Immunotherapy Treatment ONCOS-102: News Keeps Getting Better
Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect. Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival
A comparison of chemotherapy alone versus surgery-based tri-modality treatment for mesothelioma shows patients who take the more aggressive path tend to live much longer. Malignant pleural mesothelioma is a rare cancer with a poor prognosis. Many patients die within a year of diagnosis. Chemotherapy is the most common treatment. But chemotherapy alone is rarely enough to stop this aggressive cancer. Tri-modality mesothelioma treatment combines several different types of therapies. The goal is to attack mesothelioma from different angles. Now, a new study suggests that patients who go this route triple their survival over those who choose more conservative treatment. Surgery-Based Tri-Modality Mesothelioma Treatment Pleural mesothelioma is a fast-growing malignancy on the lining around the lungs. It is almost always caused … Continue reading Tri-modality Mesothelioma Treatment Triples Survival Time in New Study
The best mesothelioma surgery is the one the patient can tolerate with the fewest serious side effects. That’s according to a new study from MD Anderson researchers. Their goal was to help settle the ongoing debate over which type of pleural mesothelioma surgery is most effective. Both EPP and P/D surgery are major operations. But one causes much more serious side effects than the other. So how do doctors and patients decide on the best mesothelioma surgery for their case? The new research suggests there may not be a definitive answer. Debate Over the Best Mesothelioma Surgery Pleural mesothelioma is an asbestos-linked cancer of the membrane around the lungs. During EPP (extrapleural pneumonectomy) surgery, doctors remove this membrane, any other … Continue reading Study Asks What is the Best Mesothelioma Surgery?
The makers of the immunotherapy treatment ONCOS-102 have released promising new data on its ability to promote long-term mesothelioma survival. The report came less than two weeks after ONCOS-102 got FDA approval to fast-track its development. ONCOS-102 is an investigational treatment made from a modified virus. The virus helps the treatment target mesothelioma cells while leaving healthy cells alone. The new long-term mesothelioma survival data shows half of people on ONCOS-102 and chemotherapy have lived for 21 months. And the study is not over yet. Typical survival with standard mesothelioma chemotherapy is about a year. Targovax says the data shows how valuable ONCOS-102 could be for patients with this rare but aggressive malignancy. Standard of Care for Pleural Mesothelioma Pleural … Continue reading Long-Term Mesothelioma Survival with ONCOS-102
Scientists think they now have a better understanding of why most women with mesothelioma live longer than men. Malignant mesothelioma is four times more common in men than in women. But many studies show that women with mesothelioma do better than men after treatment. Researchers with The International Mesothelioma Program at Brigham and Women’s Hospital in Boston say the difference is in the genes. Their new study focused on the potentially protective role of estrogen signaling genes in female patients. The RERG Gene and Mesothelioma Survival In the latest study, researchers analyzed genetic data and survival in groups of mesothelioma patients. The groups included both men and women with mesothelioma. The goal was to determine what aspect of the women’s … Continue reading Estrogen Signaling Genes May be Secret to Survival for Women with Mesothelioma
Italian researchers say metabolic markers may hold the key to predicting radiotherapy outcomes in people with mesothelioma. Metabolism is the process by which cells produce energy. Metabolism is necessary for cancer cells to live. Mesothelioma cells metabolize faster than healthy cells. Radiotherapy affects cancer cell metabolism. A new study shows that compounds produced during metabolism may impact radiotherapy outcomes. It suggests that a patient’s metabolic profile – or metabolome – could help doctors choose good candidates for radiation. Radical Hemithoracic Radiotherapy and Mesothelioma Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Metabolism
A new lung cancer study suggests that having an autoimmune disease will not necessarily lead to shorter cancer survival. This could be good news for pleural mesothelioma patients suffering from autoimmune disorders. Pleural mesothelioma is a lung-related disease that has many characteristics in common with lung cancer. The new study comes from Northwestern University Feinberg School of Medicine in Chicago. It included 177 lung cancer patients who also had immune diseases. Doctors compared their survival with a control group of lung cancer patients. They determined that having an autoimmune disease did not negatively impact lung cancer survival. In fact, some of those patients lived longer than those with healthy immune systems. What is an Autoimmune Disease? An autoimmune disease is … Continue reading Autoimmune Disease and Mesothelioma: Will it Impact Survival?